 |
autologous CD4+/CD8+ T cells expressing a CD19 chimeric antigen receptor and truncated epidermal growth factor receptor |
|---|---|
| Trade Name | |
| Orphan Indication | Diffuse Large B-cell Lymphoma |
| USA Market Approval | USA |
| USA Designation Date | 2016-04-27 00:00:00 |
| Sponsor | Juno Therapeutics, Inc.;400 Dexter Avenue North, Suite 1200;Seattle, Washington, 98109 |
